Predictors and Outcomes of Intensive Care Utilization in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant at Mayo Clinic, Florida  by Jacks, Demetria Ileana et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S253(10.3%) were attributed to bacterial infection. Risk factors
associated with higher risk of bacterial infections included
age < 2 years at transplantation (p¼0.001), use of PB
(p¼0.038), myeloablative conditioning (p¼0.027), mis-
matched or unrelated donor (p¼ 0.002), family donors other
than identical siblings (p¼0.046), use of TPN (p¼0.046), and
morphine use for more than 5 days (p¼0.011) due to
signiﬁcant mucositis. In a multivariate analysis; age at
transplantation < 2 years (HR¼6.834; 95% CI 1.528-30.572;
p¼0.0119) was the only factor associated with higher risk for
bacterial infection post HSCT.
Conclusion: Bacterial infections are common following
allogeneic HSCT in children and adolescents not receiving
antibiotic prophylaxis and are associatedwith signiﬁcant risk
of mortality. Children below 2 years of age are at higher risk.
We have prospectively implemented an antibiotic prophy-
laxis regimen in an effort to decrease bacterial infections.352
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Introduction: Cytomegalovirus (CMV) infection is a known
complication following allogeneic hematopoietic stem cell
transplantation (HSCT). The method and duration of CMV
monitoring are center-dependent, and no standards on the
effective duration of CMV surveillance are clearly reported in
the literature especially in areas with high CMV exposure.
Patients and Methods: We retrospectively reviewed the
medical records of all consecutive patients who received
allogeneic HSCT between January 2008 and April 2014 at
King Hussein Cancer Center (KHCC) in Jordan. The CMV
infectionwasmonitored using pp65 antigenemia test weekly
from time of neutrophil engraftment until day 100 post
transplantation. Treatment with gancyclovir was initiated
when two consecutive positive antigenemia tests of more
than two cells per 250 WBC were documented. All patients
received leukoﬁltered and irradiated blood products.
Results: A total of 200 patients were identiﬁed, with median
age of 9 year (2 months-27 year). Sixty percent (n¼119) were
males. One hundred and nineteen patients (60%) had non-
malignant diseases. Peripheral blood (PB) was the stem cell
source in 110 (55%), 69 (34.5%) received bone marrow and 21
patients (10.5%) received cord blood. Sixty nine percent
received myeloablative conditioning (n¼137), 26% reduced
intensity (n¼52) and 5% no conditioning regimen (n¼11).
Ninety-one percent (n¼182) were matched-related (140
were HLA identical siblings and 42 were other family
donors). Ninety three percent of our patients (n¼186) and
83% of donors (n¼166) were CMV sero positive. Thirty-ﬁve
patients (17.5%) needed preemptive therapy for CMV
reactivation at a median of 33 days (14-70) following
transplantation. The median number of cells was one cell per
250 WBC (1-2298). Ten patients continued to have positive
CMV antigenemia on day 70, and 3 on day 100, while only
one patient had new episode of CMV reactivation after 70
days post transplantation. Two patients (1%) developed CMVdisease (pneumonitis and colitis). In univariate analysis,
patients who received ATG (p¼0.005), non-sibling related
donors (p¼0.037), mismatched or unrelated donor
transplants (p¼0.007), PB (p¼0.019), and myeloablative
conditioning (p¼0.004) were at higher risk for developing
CMV reactivation. In multivariate analysis; ATG use
(HR¼2.87; 95% CI 1.026-8.025; p¼0.0445) and the use of
mismatched related or unrelated donor (HR¼11.11; 95% CI
1.87-66.67, p¼0.0081) was associated with increased risk of
CMV reactivation.
Conclusion: The incidence of CMV reactivation following
allogeneic HSCT in children and adolescents within high
CMV exposure population is low. Shortening the duration of
CMV surveillance may be feasible. Use of ATG in the
preparative regimen and those receiving mismatched or
alternative donor transplants are at the highest risk for CMV
reactivation.353
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To understand predictors and outcomes of ICU admissionwe
conducted a retrospective study of consecutive patients
undergoing allogeneic HCTover a 10 year period 1/2002 - 12/
2012. Information about patient demographics, disease
characteristics, disease status, co-morbidities, conditioning
regimen, donor characteristics and ICU interventions were
collected. Single and multivariable analysis was used to
assess associations between various characteristics and
outcomes. Survival probabilities were estimated using the
Kaplan-Meier method.
118 patients underwent ﬁrst transplant. Median age was
51 (range 20-72); 81% had leukemia. 39 (33%) patients were
admitted to the ICU within the ﬁrst 100 days; 22 within 14
days of transplant. Median survival of these patients was 54
days (95% CI 14-189) compared to 4.5 years for patients not
admitted to ICU. In single variable analysis, TBI (p¼0.04),
URD (p¼0.03), mismatched donor (p¼0.009)*, and not in CR
(p<0.001)* were associated with increased likelihood of
ICU admission (*signiﬁcance in multivariable analysis).
HCT-CI score was not found to be associated with ICU
admission.
Increased risk of death in ICU patients was associated with
male sex (p<0.001), HCT-CI deﬁned liver dysfunction
(p¼0.003) and vasopressor administration (p¼0.020) in
single variable analysis. Adjusting for sex (HR¼4.63),
vasopressor administration (HR 4.54, p¼0.001) and number
of ICU interventions within 48 hours of admission (HR 3.48
[>1 vs 0], p¼ 0.026) were associated with increased risk of
death. APACHE score was not associated.
Compared to females, male patients had higher rates of
myeloablative regimens (71% v 56%), TBI (48% v 33%), URD
HCT (76% v 44%) and vasopressor use (33% v 24%) as well as
lower rates of CR (19% v 28%) at time of transplant.
ICU admissionwas associated with an increased risk of death
(HR¼ 3.70, 95% CI 2.26-6.06, p<0.001). ICU survivors tended
to have worse long-term outcomes. Among 18 patients alive
at day 90, 12 survived to one year (67%) compared to 61 out
of 79 (77%) who never required ICU admission (p¼0.84).
Further analysis to understand the causes of worse outcomes
Figure 1. Survival among patients alive at 90 days after transplant according
to whether they were admitted to the ICU within 90 days after transplant.
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survivors warrant validation in a larger cohort and further
research to understand its mechanism and develop
appropriate strategies. Our study is limited by type II and
type I errors due to small sample size and multiple variables.
Nonetheless, these results provide potentially important
data for patient counseling andmay help guide management
of critical illness post-transplant.354
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Background: In 2011, the American Society of Clinical
Oncology (ASCO) and the Oncology Nursing Society (ONS)
expanded the scope of their 2009 guidelines to address
chemotherapy administration safety in the inpatient setting
(Jacobson, J., Polovich, M., et al., 2012). The guidelines
encompass physician, pharmacy and nursing practices sur-
rounding chemotherapy ordering, processing and delivery. A
review of our current processes elucidated opportunity for
improvement.
Objectives: To develop and implement processes promoting
multidisciplinary congruency with the ASCO/ONS guidelines
across our BMT, Hematology and Oncology Inpatient and
Ambulatory Care units.
To safeguard administration of chemotherapy.
Interventions: Our initial step involved updating our
chemotherapy administration policy for pharmacy and
nursing to include recommendations from ONS/ASCO. The
policy underwent multiple revisions by nursing, pharmacy
and the medical staff prior to approval in July, 2013. Once
approved, we developed a checklist for both pharmacy and
nursing use to help ensure all required elements were
addressed in the order sets prior to processing a chemo-
therapy order. A separate checklist was created for RN use
before and after chemotherapy administration. Finally, we
revised the chemotherapy order template for physicians to
use in the absence of a pre-printed order set. RN staff,
oncology pharmacists and the oncologists were in-serviced
on the new policy, order sets and checklists. Beginning in
September, 2013, audits were performed on all returned
checklists.Evaluation: In the ﬁrst months following implementation
of the policy, compliance with completion of the checklists
was less than 50%. RN champions agreed to audit 100% of
the chemotherapy doses ordered and administered.
Pharmacy and Nursing compared their orders for the
month to ensure there were no missing checklists.
Compliance data was shared with the staff on the Oncology/
Blood Cancer/BMT Units and individual performance
deﬁcits were addressed. Audits of all orders and
checklists were continued until greater than 90% compliance
was reached. Audits are now done quarterly to monitor
continued compliance.355
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With changing immunomodulation, prophylactic and
empiric therapy in HSCT patients, continual reassessment of
infecting pathogens and rates of recovery are required as
infections remain a leading cause of morbidity andmortality.
We performed a retrospective chart review of 86 BMT
patients who underwent allogeneic HSCT (AlloSCT) or
autologous HSCT (ASCT) from 7/11 to 4/14 and with 100 days
of post-transplant follow-up. Evaluation included pathogen
detection and recovery from D0-30 and D31-100 (deﬁned as
one set of testing per 24h period).
Therewere 86 patients, 30 AlloSCT (median age 35, 20-66)
and 56 ASCT (median age 55, 20-72). Age and gender had no
statistically signiﬁcant effect on overall mortality. 100% of
patients underwent evaluations for infection. Of 406 total
samples obtained, only 22 (5%) revealed a pathogen. 158 (119
D0-30, 39 D31-100) blood culture evaluations were obtained
in 66 patients (50 D0-30, 16 D31-100) with only 10 (5 D0-30,
5 D31-100) positive evaluations in 8 patients. Overall, 11% of
ASCT and 14% of AlloSCT patients had clinically signiﬁcant
bacteremia. 96 (71 D0-30, 25 D31-100) urine cultures were
obtained in 55 patients with 3 (0 D0-30, 3 D31-100) positive
evaluations in 2 patients resulting in 0% of ASCT and 7% of
AlloSCT with clinically signiﬁcant bacteriuria. 152 (130
D0-30, 22 D31-100) C. diff tests were obtained in 77 patients
with 9 positive evaluations in 8 patients (6 D0-30, 2
D31-100) resulting in a C. diff detection rate of 12% and 11% in
ASCT and AlloSCT patients, respectively. All-cause mortality
was 14% (7% ASCT, 27% AlloSCT; p ¼ 0.021). Of patients with
positive blood, urine, and C.diff testing, mortality was 50% (p
¼ 0.020), 100% (p ¼ 0.042), and 25% (0.003), respectively. No
patients died during D0-D100. After D100, infection-related
mortality was 25%.
Actionable infections require rapid detection in BMT
patients. Clinical parameters often trigger extensive evalua-
tions but our diagnostic yield was < 15%. Infections during
D0-D100 were associated with greater all-cause mortality
and 25% of post-transplant death was attributed to infection.
While current empiric therapy has reduced infection rates,
improved clinical algorithms and methods of pathogen
detection are needed to improve HSCT care.
